Skip to content

Clinical study on feibi granule in treating patients with coal worker's pneumoconiosis in remission stage

Clinical study on feibi granule in treating patients with coal worker's pneumoconiosis in remission stage

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006865
Enrollment
Unknown
Registered
2022-12-14
Start date
2022-12-20
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coal-worker's pnuemoconiosis

Interventions

Experimental Group:Routine treatment and Feibi granule
Control Group:Routine treatment and Feibi granule placebo

Sponsors

Fangshan Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)The coal workers' pneumoconiosis patients of stage I, II and III diagnosed by the occupational disease appraisal institution (2)Meeting the criteria for the remission period (3)It is in accordance with the diagnostic standard of syndrome of deficiency of lung-qi and obstruction of collaterals by phlegm and blood stasis (4)Older than 18 years (5)Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1)Patients report being pregnant/lactating (2)Patients report with mental illness (3)Patients report that they are complicated with respiratory failure, cor pulmonale, pulmonary-cerebral syndrome and severe pulmonary infection (4)Patients with other diseases need to take other traditional Chinese medicine preparations for more than 4 weeks (5)Patients report being enrolled in other clinical trials (6)Patients report allergic constitution or drug allergy to the subject.

Design outcomes

Primary

MeasureTime frame
the modified British Medical Research Council(mMRC);

Secondary

MeasureTime frame
TCM symptom integral scale;Human surfactant protein D;the MOS item short from health survey, SF-36;Human surfactant protein A;Chest computed tomography;Six-minute walk test;Pulmonary function;

Countries

China

Contacts

Public ContactBai Xiaoxu
bxx1119@163.com15210723050

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026